Recrutamento encerrado
FASE
Número Europeu 2019-004773-29
GO41854 SKYSCRAPER-03
A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation
Detalhes
Destaques